American Society of Clinical Oncology

SHERPA: White

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. O'Reilly
    O'Reilly
  4. Saltz
    Saltz
  5. Bajorin
    Bajorin
  6. Kris
    Kris
  7. Hudis
    Hudis
  8. Morris
    Morris
  9. Rosenberg
    Rosenberg
  10. Robson
    Robson

Groups

  1. Department of Medicine (6409)
  2. Solid Tumor Oncology Division (5547)
  3. Survivorship Research (2000)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1642)
  6. Epidemiology and Biostatistics (1497)
  7. GSK Faculty (1389)
  8. Population Sciences Research Program (1382)
  9. Gastrointestinal Oncology Service (1356)
  10. Hematologic Malignancies, Division of (1286)
Search Within
Formats
  1. Meeting Abstract (6344)
  2. Journal Article (2591)
  3. Editorial (79)
  4. Review (70)
  5. Guidelines (55)
  6. Correspondence (49)
  7. Miscellaneous (4)
  8. Conference Paper (3)
Groups
  1. Department of Medicine (6409)
  2. Solid Tumor Oncology Division (5547)
  3. Survivorship Research (2000)
  4. Genitourinary Oncology Service (1768)
  5. Surgery (1642)
  6. Epidemiology and Biostatistics (1497)

More Groups

People
  1. Robert Motzer (451)
  2. Howard Scher (334)
  3. Eileen O'Reilly (308)
  4. Leonard Saltz (283)
  5. Dean Bajorin (280)
  6. Mark Kris (253)

More People

Years
  1. 2025 (303)
  2. 2024 (554)
  3. 2023 (580)
  4. 2022 (554)
  5. 2021 (504)
  6. 2020 (539)

More Years

Publications
  1. Journal of Clinical Oncology (8712)
  2. JCO Precision Oncology (174)
  3. Journal of Oncology Practice (124)
  4. American Society of Clinical Oncology Educational Book (112)
  5. JCO Clinical Cancer Informatics (54)
  6. JCO Oncology Practice (12)

More Publications

Results (9195)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety analysis by treatment periods from EMERALD-1: A phase 3, randomized, placebo-controlled study of transarterial chemoembolization with durvalumab with/without bevacizumab in participants with embolization-eligible unresectable hepatocellular carcinoma
    Meeting Abstract

    Kudo, M.; Chan, S. L.; Sangro, B.; Erinjeri, J. P.; Qin, S.; Ren, Z.; Arai, Y.; Breder, V. V.; Lin, S. M.; Peron, J. M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Health disparity viewed from public historic cancer mortality data in the US: Advocacy for gastrointestinal cancers, for tailored prevention measures, and for inter-agency population data harmonization
    Meeting Abstract

    Zhang, T.; Hung, T.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Retrieval-augmented large language models for clinical trial screening
    Meeting Abstract

    He, J.; Gai, S.; Ho, S. X.; Chua, S. L.; Oo, V.; Zaw, M. W. W.; Tan, D. S. W.; Tan, R.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient-reported outcomes in patients with advanced urothelial cancer who are ineligible for cisplatin and treated with first-line enfortumab vedotin alone or with pembrolizumab
    Journal Article

    Milowsky, M. I.; O'Donnell, P. H.; Hoimes, C. J.; Petrylak, D. P.; Flaig, T. W.; Moon, H. H.; Friedlander, T. W.; Mar, N.; McKay, R. R.; Srinivas, S.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Tumor size is not everything: Advancing radiomics as a precision medicine biomarker in oncology drug development and clinical care. A report of a multidisciplinary workshop coordinated by the RECIST Working Group
    Journal Article

    Nakajima, E. C.; Simpson, A.; Bogaerts, J.; de Vries, E. G. E.; Do, R.; Garralda, E.; Goldmacher, G.; Kinahan, P. E.; Lambin, P.; LeStage, B.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • PD-L1 immunohistochemistry in gastric cancer: Comparison of combined positive score and tumor area positivity across 28-8, 22C3, and SP263 assays
    Journal Article

    Klempner, S. J.; Cowden, E. S.; Cytryn, S. L.; Fassan, M.; Kawakami, H.; Shimada, H.; Tang, L. H.; Wagner, D. C.; Yatabe, Y.; Savchenko, A.; more...
    JCO Precision Oncology (2024)

    Fulltext@MSK | Save
  • Reply to J.A. Garcia et al
    Correspondence

    Halabi, S.; Guo, S.; Roy, A.; Rydzewska, L. E.; Godolphin, P.; Hussain, M.; Tangen, C.; Thompson, I.; Xie, W.; Carducci, M. A.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Clinical and genomic-based decision support system to define the optimal timing of allogeneic hematopoietic stem-cell transplantation in patients with myelodysplastic syndromes
    Journal Article

    Tentori, C. A.; Gregorio, C.; Robin, M.; Gagelmann, N.; Gurnari, C.; Ball, S.; Berrocal, J. C. C.; Lanino, L.; D'Amico, S.; Spreafico, M.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Patient-reported outcomes from the phase III HIMALAYA study of Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma
    Journal Article

    Sangro, B.; Galle, P. R.; Kelley, R. K.; Charoentum, C.; De Toni, E. N.; Ostapenko, Y.; Heo, J.; Cheng, A. L.; Wilson Woods, A.; Gupta, C.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • Reply to A.S. Garden
    Correspondence

    Lee, N. Y.; Sherman, E. J.; Riaz, N.
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save